PFIZER LIMITED

Maintain abilty of Minister to grant exemptions by not repealing section 1237(5) of the Companies Act 2014 under which Pfizer had secured exemptions for five out of seventeen Irish entities; or introduce an additional amendment to address the disproportionate burden of this…

Highlight delays in the reimbursement process, inquire about status of reimbursement of Pfizer's medicine for metatastic breast cancer, which was approved in the EU by the EMA in November 2016, through question to Minister for Health and build understanding that patients with…

Improve access to innovative medicines for Irish patients by highlighting the current delays at every stage in the process

Maintain abilty of Minister to grant exemptions by not repealing section 1237(5) of the Companies Act 2014 under which Pfizer had secured exemptions for five out of seventeen Irish entities; or introduce an additional amendment to address the disproportionate burden of this…

Highlight delays in the reimbursement process, inquire about status of reimbursement of Pfizer's medicine for metatastic breast cancer, which was approved in the EU by the EMA in November 2016, through question to Minister for Health and build understanding that patients with…

Highlight the importance of Ireland's pro-enterprise policies such as competitive corporate tax policies, investment in science education, medicine access and pricing policies, regulatory access.

Highlight concerns about delays in the reimbursement process and inquire about status of medicines currently in the reimbursement process through question to Minister for Health.

Highlight potential patient safety concerns about FF private member bill designed to amend the Health Act 2013 to allow biologic medicines be deemed interchangeable, which if so designated by the regulator, would mean that a pharmacist could provide a biosimilar version of the…

Highlight the importance of a competitive corporate tax framework for international investment in Ireland

Build understanding of the significance of the savings being provided, the mechanisms involved and how this creates significant headroom to reimburse new medicines ensuring Irish patients have timely access to innovative medicines

Build understanding that patients with metastatic breast cancer need new treatments and Pfizer will start seeking reimbursement for Ibrance in Ireland and is hopeful that timely reimbursement will be secured so that patients can get access to this first new therapy in over 10…